Should I buy or sell Grifols stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Grifols in the last twelve months. There are currently 1 sell rating and 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "reduce" GRFS shares. View GRFS analyst ratings or view top-rated stocks .

What is Grifols' stock price target for 2024?

3 brokers have issued 1 year price targets for Grifols' stock. Their GRFS share price targets range from $10.50 to $10.50. On average, they anticipate the company's share price to reach $10.50 in the next year. This suggests a possible upside of 62.0% from the stock's current price. View analysts price targets for GRFS or view top-rated stocks among Wall Street analysts .

How have GRFS shares performed in 2024?

Grifols' stock was trading at $11.56 at the beginning of the year. Since then, GRFS shares have decreased by 43.9% and is now trading at $6.48. View the best growth stocks for 2024 here .

Are investors shorting Grifols?

Grifols saw a decrease in short interest in March. As of March 31st, there was short interest totaling 5,970,000 shares, a decrease of 27.1% from the March 15th total of 8,190,000 shares. Based on an average trading volume of 3,250,000 shares, the short-interest ratio is currently 1.8 days. Approximately 2.3% of the company's shares are sold short. View Grifols' Short Interest .

How were Grifols' earnings last quarter?

Grifols, S.A. (NASDAQ:GRFS) issued its quarterly earnings data on Tuesday, May, 4th. The biotechnology company reported $0.21 earnings per share for the quarter, missing the consensus estimate of $0.22 by $0.01. The biotechnology company earned $1.43 billion during the quarter. Grifols had a net margin of 1.84% and a trailing twelve-month return on equity of 1.73%.

What ETF holds Grifols' stock?

First Trust NYSE Arca Biotechnology Index Fund holds 4,612,158 shares of GRFS stock, representing 3.48% of its portfolio.

When did Grifols' stock split?

Grifols's stock split before market open on Monday, January 4th 2016. The 2-1 split was announced on Thursday, December 3rd 2015. The newly issued shares were distributed to shareholders after the closing bell on Thursday, December 31st 2015. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

What guidance has Grifols issued on next quarter's earnings?

Grifols updated its FY 2024 earnings guidance on Thursday, February, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $7.6 billion-, compared to the consensus revenue estimate of $7.7 billion.

What is Raimon Grifols and Victor Grifols Deu's approval rating as Grifols' CEO?

205 employees have rated Grifols Chief Executive Officer Raimon Grifols and Victor Grifols Deu on Glassdoor.com . Raimon Grifols and Victor Grifols Deu has an approval rating of 68% among the company's employees.

What other stocks do shareholders of Grifols own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Grifols investors own include Gilead Sciences (GILD) , Pfizer (PFE) , Teva Pharmaceutical Industries (TEVA) , Abbott Laboratories (ABT) , Alibaba Group (BABA) , Johnson & Johnson (JNJ) , NVIDIA (NVDA) , AbbVie (ABBV) , Bristol-Myers Squibb (BMY) and Nektar Therapeutics (NKTR) .

Who are Grifols' major shareholders?

Grifols' stock is owned by a variety of institutional and retail investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.00%).

How do I buy shares of Grifols?

Shares of GRFS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Does Grifols have any subsidiaries?

The following companies are subsidiares of Grifols: Aigües Minerals de Vilajuiga S.A., Araclon Biotech, Araclon Biotech S.L., Asociación I+D Progenika, Biomat S.A., Biomat USA Inc., Biotest Pharmaceutical Corporation, Biotest US Corporation, Chiquito Acquisition Corp., Diagnostic Grifols S.A., Goetech LLC (D/B/A Medkeeper), Gri-Cel S.A. , Grifols (H.K.) Limited, Grifols (Thailand) Ltd, Grifols Argentina S.A., Grifols Asia Pacific Pte Ltd, Grifols Australia Pty Ltd., Grifols Biologicals LLC., Grifols Brasil Lda., Grifols Canada Ltd., Grifols Chile S.A., Grifols Colombia Ltda, Grifols Deutschland GmbH, Grifols Diagnostics Equipment Taiwan Limited, Grifols Diagnostics Solutions Inc, Grifols Engineering S.A., Grifols France S.A.R.L., Grifols India Healthcare Private Ltd, Grifols Innovation and New Technologies Limited, Grifols International S.A., Grifols Italia S.p.A, Grifols Japan K.K., Grifols Malaysia Sdn Bhd, Grifols Movaco S.A., Grifols México S.A. de C.V., Grifols Nordic AB, Grifols Pharmaceutical Technology (Shanghai) Co. Ltd., Grifols Polska Sp.z.o.o., Grifols Portugal Productos Farmacéuticos e Hospitalares Lda., Grifols Shared Services North America Inc., Grifols Switzerland AG, Grifols Therapeutics LLC., Grifols UK Ltd., Grifols USA LLC., Grifols Viajes S.A., Grifols Worldwide Operations Limited, Grifols Worldwide Operations Spain S.A., Grifols Worldwide Operations USA Inc., Grifols s.r.o., Gripdan Invest S.L, Haema AG, Instituto Grifols S.A., Interstate Blood Bank Inc., Kiro Grifols S.L, Kiro Robotics, Laboratorios Grifols S.A., Logística Grifols S.A. de C.V., Medion Diagnostics GmbH, Medion Grifols Diagnostic AG, PBS Acquisition Corp., Progenika Biopharma, Progenika Biopharma S.A., Squadron Reinsurance Designated Activity Company, Talecris Biotherapeutics, Talecris Plasma Resources Inc., and VCN Bioscience S.L.. Read More

NASDAQ:GRFS

Grifols (GRFS) Stock Price, News & Analysis

→ The Next Nvidia? (From InvestorPlace) (Ad)

Free GRFS Stock Alerts

$6.54

-0.04 (-0.61%)

(As of 05:17 PM ET)

Compare

Today's Range: $6.46
▼
$6.64
50-Day Range: $5.47
▼
$9.34
52-Week Range: $5.30
▼
$12.15

Volume: 760,142 shs
Average Volume: 2.99 million shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.50

Get Grifols alerts:

Grifols MarketRank™ Stock Analysis

Analyst Rating: Reduce
1.67 Rating Score
Upside/Downside: 62.0% Upside
$10.50 Price Target
Short Interest: Healthy
2.32% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.33
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 60.00%
From $0.85 to $1.36 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.30 out of 5 stars

2.8

Analyst's Opinion

Consensus Rating
Grifols has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no buy ratings, 2 hold ratings, and 1 sell rating.
Amount of Analyst Coverage
Grifols has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
2.32% of the float of Grifols has been sold short.
Short Interest Ratio / Days to Cover
Grifols has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Grifols has recently decreased by 27.11%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Grifols does not currently pay a dividend.
Dividend Growth
Grifols does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for GRFS.

1.3

News and Social Media Coverage

News Sentiment
Grifols has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Grifols this week, compared to 3 articles on an average week.
Search Interest
Only 1 people have searched for GRFS on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Grifols to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Grifols insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.19% of the stock of Grifols is held by insiders.

3.8

Earnings and Valuation

Earnings Growth
Earnings for Grifols are expected to grow by 60.00% in the coming year, from $0.85 to $1.36 per share.
Price to Earnings Growth Ratio
Grifols has a PEG Ratio of 0.27. PEG Ratios below 1 indicate that a company could be undervalued.
Price to Book Value per Share Ratio
Grifols has a P/B Ratio of 0.51. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

The Next Nvidia?

The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.

Go here now for this breaking story.

About Grifols Stock (NASDAQ:GRFS)

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.

GRFS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

GRFS Stock News Headlines

April 18, 2024 | globenewswire.com

Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.

April 15, 2024 | msn.com

Grifols reportedly looking to appoint independent directors

April 18, 2024 | InvestorPlace (Ad)

The Next Nvidia?

April 14, 2024 | reuters.com

Spanish drug maker Grifols will bring in independent directors, chairman tells newspaper

April 10, 2024 | reuters.com

Grifols to refinance debt due in 2025 via sales of notes, Shanghai RAAS stake

April 4, 2024 | yahoo.com

Spain's Grifols gives new details on past EBITDA, leverage ratios to supervisor

April 4, 2024 | finanznachrichten.de

Grifols, S.A.: Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening

April 4, 2024 | globenewswire.com

Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening

April 18, 2024 | InvestorPlace (Ad)

The Next Nvidia?

April 1, 2024 | msn.com

European Equities Traded in the US as American Depositary Receipts Start Week Modestly Higher

March 27, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Grifols S.A. - GRFS

March 22, 2024 | uk.finance.yahoo.com

Grifols’ Financials Have No Big Errors, Spain Regulator Says

March 19, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Grifols S.A. - GRFS

March 16, 2024 | finance.yahoo.com

GRFS Nov 2024 3.000 put

March 16, 2024 | finance.yahoo.com

GRFS Apr 2024 11.000 call

March 14, 2024 | stockhouse.com

Grifols S.A. (GRFS - ADR ADR Class B) Shares Decline Again After Gotham City Research Issues Another Critical Report - Hagens Berman

March 14, 2024 | msn.com

Grifols slips as Fitch, S&P cut credit ratings

March 14, 2024 | msn.com

Grifols Gets Downgraded: Fitch, S&P Flag Cash Flow Concerns At Pharma Company

March 14, 2024 | msn.com

Shares in Spanish drugmaker Grifols tumble on Fitch, S&P downgrades

March 11, 2024 | markets.businessinsider.com

GRFS Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Grifols S.A. (GRFS) Investors to Contact the Firm

March 11, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Grifols S.A. - GRFS

March 6, 2024 | msn.com

Grifols falls amid potential Moody's downgrade, new short report

March 6, 2024 | finance.yahoo.com

Spanish Healthcare Firm Grifols Hit With New Gotham City's Short Report, Faces Questions Regarding Transparency, Integrity, Ethical Conduct

March 6, 2024 | reuters.com

Grifols shares drop to 12-year low after new Gotham City Research report

March 6, 2024 | reuters.com

Grifols shares drop 15% after new Gotham City Research report

March 5, 2024 | seekingalpha.com

Grifols: Q4 Was Positive, Still Too Many Question Marks

March 1, 2024 | reuters.com

Grifols says due diligence done, Shanghai RAAS stake sale to go ahead

See More Headlines

Receive GRFS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Grifols and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 5/04/2021
Today: 4/18/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:GRFS
CUSIP: N/A
CIK: 1438569
Web: www.grifols.com
Phone: (493) 571-0221
Fax: 34-93-571-0267
Employees: 26,314
Year Founded: 1909

Price Target and Rating

Average Stock Price Target: $10.50
High Stock Price Target: $10.50
Low Stock Price Target: $10.50
Potential Upside/Downside: +59.6%
Consensus Rating: Reduce
Rating Score (0-4): 1.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: 7.74
P/E Growth: 0.27
Net Income: $131.34 million
Net Margins: 1.84%
Pretax Margin: 3.40%
Return on Equity: 1.73%
Return on Assets: 0.66%

Debt

Debt-to-Equity Ratio: 1.24
Current Ratio: 2.83
Quick Ratio: 1.32

Sales & Book Value

Annual Sales: $7.13 billion
Price / Sales: N/A
Cash Flow: $0.77 per share
Price / Cash Flow: 8.59
Book Value: $12.61 per share
Price / Book: 0.52

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Optionable
Beta: 0.56

Social Links

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Mr. Thomas H. Glanzmann (Age 66)
CEO & Executive Chairman
Comp: $162.48k
Mr. Alfredo Arroyo Guerra (Age 66)
CFO & VP
Mrs. Eva Bastida Tubau
Corporate Vice President and Director of Scientific & Medical Affairs
Ms. Nuria Pascual Lapeña (Age 60)
VP of Corporate Treasury, Risk Management Investor Relation & Sustainability Officer
Mr. David Ian Bell (Age 70)
Chief Corporate Development, Legal & Data Protection Officer
Ms. Maria Teresa-Rioné Llano (Age 59)
Chief Communications Officer
Ms. Montserrat Gaja Llamas (Age 59)
Chief Human Resources Officer
Mr. Vicente Blanquer Torre (Age 63)
Chief Quality Officer
Mr. Alberto Grifols Roura (Age 65)
President of the Bio Supplies Division
Mr. Sergio Roura Adell (Age 56)
President of Commercial Tech Support

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

GRFS Stock Analysis - Frequently Asked Questions

Should I buy or sell Grifols stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Grifols in the last twelve months. There are currently 1 sell rating and 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "reduce" GRFS shares.
View GRFS analyst ratings or view top-rated stocks.
What is Grifols' stock price target for 2024?: 3 brokers have issued 1 year price targets for Grifols' stock. Their GRFS share price targets range from $10.50 to $10.50. On average, they anticipate the company's share price to reach $10.50 in the next year. This suggests a possible upside of 62.0% from the stock's current price.
View analysts price targets for GRFS or view top-rated stocks among Wall Street analysts.
How have GRFS shares performed in 2024?: Grifols' stock was trading at $11.56 at the beginning of the year. Since then, GRFS shares have decreased by 43.9% and is now trading at $6.48.
View the best growth stocks for 2024 here.
Are investors shorting Grifols?: Grifols saw a decrease in short interest in March. As of March 31st, there was short interest totaling 5,970,000 shares, a decrease of 27.1% from the March 15th total of 8,190,000 shares. Based on an average trading volume of 3,250,000 shares, the short-interest ratio is currently 1.8 days. Approximately 2.3% of the company's shares are sold short.
View Grifols' Short Interest.
How were Grifols' earnings last quarter?: Grifols, S.A. (NASDAQ:GRFS) issued its quarterly earnings data on Tuesday, May, 4th. The biotechnology company reported $0.21 earnings per share for the quarter, missing the consensus estimate of $0.22 by $0.01. The biotechnology company earned $1.43 billion during the quarter. Grifols had a net margin of 1.84% and a trailing twelve-month return on equity of 1.73%.
What ETF holds Grifols' stock?: First Trust NYSE Arca Biotechnology Index Fund holds 4,612,158 shares of GRFS stock, representing 3.48% of its portfolio.
When did Grifols' stock split?: Grifols's stock split before market open on Monday, January 4th 2016. The 2-1 split was announced on Thursday, December 3rd 2015. The newly issued shares were distributed to shareholders after the closing bell on Thursday, December 31st 2015. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

What guidance has Grifols issued on next quarter's earnings?: Grifols updated its FY 2024 earnings guidance on Thursday, February, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $7.6 billion-, compared to the consensus revenue estimate of $7.7 billion.
What is Raimon Grifols and Victor Grifols Deu's approval rating as Grifols' CEO?: 205 employees have rated Grifols Chief Executive Officer Raimon Grifols and Victor Grifols Deu on Glassdoor.com. Raimon Grifols and Victor Grifols Deu has an approval rating of 68% among the company's employees.
What other stocks do shareholders of Grifols own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Grifols investors own include Gilead Sciences (GILD), Pfizer (PFE), Teva Pharmaceutical Industries (TEVA), Abbott Laboratories (ABT), Alibaba Group (BABA), Johnson & Johnson (JNJ), NVIDIA (NVDA), AbbVie (ABBV), Bristol-Myers Squibb (BMY) and Nektar Therapeutics (NKTR).
Who are Grifols' major shareholders?: Grifols' stock is owned by a variety of institutional and retail investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.00%).
How do I buy shares of Grifols?: Shares of GRFS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
Does Grifols have any subsidiaries?: The following companies are subsidiares of Grifols: Aigües Minerals de Vilajuiga S.A., Araclon Biotech, Araclon Biotech S.L., Asociación I+D Progenika, Biomat S.A., Biomat USA Inc., Biotest Pharmaceutical Corporation, Biotest US Corporation, Chiquito Acquisition Corp., Diagnostic Grifols S.A., Goetech LLC (D/B/A Medkeeper), Gri-Cel S.A. , Grifols (H.K.) Limited, Grifols (Thailand) Ltd, Grifols Argentina S.A., Grifols Asia Pacific Pte Ltd, Grifols Australia Pty Ltd., Grifols Biologicals LLC., Grifols Brasil Lda., Grifols Canada Ltd., Grifols Chile S.A., Grifols Colombia Ltda, Grifols Deutschland GmbH, Grifols Diagnostics Equipment Taiwan Limited, Grifols Diagnostics Solutions Inc, Grifols Engineering S.A., Grifols France S.A.R.L., Grifols India Healthcare Private Ltd, Grifols Innovation and New Technologies Limited, Grifols International S.A., Grifols Italia S.p.A, Grifols Japan K.K., Grifols Malaysia Sdn Bhd, Grifols Movaco S.A., Grifols México S.A. de C.V., Grifols Nordic AB, Grifols Pharmaceutical Technology (Shanghai) Co. Ltd., Grifols Polska Sp.z.o.o., Grifols Portugal Productos Farmacéuticos e Hospitalares Lda., Grifols Shared Services North America Inc., Grifols Switzerland AG, Grifols Therapeutics LLC., Grifols UK Ltd., Grifols USA LLC., Grifols Viajes S.A., Grifols Worldwide Operations Limited, Grifols Worldwide Operations Spain S.A., Grifols Worldwide Operations USA Inc., Grifols s.r.o., Gripdan Invest S.L, Haema AG, Instituto Grifols S.A., Interstate Blood Bank Inc., Kiro Grifols S.L, Kiro Robotics, Laboratorios Grifols S.A., Logística Grifols S.A. de C.V., Medion Diagnostics GmbH, Medion Grifols Diagnostic AG, PBS Acquisition Corp., Progenika Biopharma, Progenika Biopharma S.A., Squadron Reinsurance Designated Activity Company, Talecris Biotherapeutics, Talecris Plasma Resources Inc., and VCN Bioscience S.L..
Read More

This page (NASDAQ:GRFS) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Grifols (GRFS) Stock Price, News & Analysis

Grifols MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Grifols Stock (NASDAQ:GRFS)

GRFS Stock Price History

GRFS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Institutional Ownership

GRFS Stock Analysis - Frequently Asked Questions

Overall MarketRank^™